Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert(Institut Gustave Roussy), Georgina V. Long(The University of Sydney), John B.A.G. Haanen(Leiden University Medical Center), Igor Bondarenko(Dnipro State Medical University), Keith T. Flaherty(Cancer Research Center), Célèste Lebbé(Inserm), Jacob Schachter, Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), E. Levchenko(Research Medical Center), Monique Tan(Heidelberg University), Axel Hauschild(University Hospital Schleswig-Holstein), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Jean‐Jacques Grob(Aix-Marseille Université), Eduard Gasal, Daniil Stroyakovskiy(Shikoku Cancer Center), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Maurizio Voi(Curis (United States)), Antoni Ribas(University of California, Los Angeles), Paul Nathan(Mount Vernon Hospital), Bogusława Karaszewska(State University of Applied Sciences in Konin), Helen Gogas(National and Kapodistrian University of Athens), Claus Garbe(University of Tübingen), Paul Burgess(Princess Alexandra Hospital), Mario Mandalà(University of Perugia)
Cited by 1,394
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k